Navigation Links
New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years
Date:10/12/2007

Treatment with AVONEX(R) (Interferon Beta-1a) for Two Years Reduces Probability of Reaching More Severe Disability Milestones at Eight Years

PRAGUE, Czech Republic, Oct. 12 /PRNewswire/ -- A post-hoc analysis from a Phase III clinical trial of AVONEX(R) (interferon beta-1a) and post-randomization eight-year follow up shows that six-month sustained progression of disability at two years, using the Expanded Disability Status Scale (EDSS), is a significant predictor of long-term disability, as measured by EDSS milestones of 4.0, 5.0, 6.0 and 7.0 at eight years, in patients with relapsing-remitting multiple sclerosis (RRMS). The analysis suggests that patients taking AVONEX for two years were less likely to experience disability progression over time (eight years) when compared to placebo. These data were announced today at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Prague, Czech Republic.

The analysis involved 160 patients with RRMS who received at least two years of treatment (81 placebo, 79 interferon beta-1a), in the AVONEX Phase III trial and who were re-examined eight years post-randomization. 45 patients met the criteria for two-year disability progression sustained for six months (n=18 AVONEX, 27 placebo). The analysis revealed:

-- Patients initially treated with AVONEX were less likely than patients

initially receiving placebo to progress to EDSS scores of greater than

or equal to 4.0 at eight years

-- Six month sustained EDSS progression during the pivotal two-year trial

was a significant predictor of disability progression eight years later

-- Almost twice as many patients who had sustained progression in EDSS

during the two-year trial progressed to an EDSS of greater than or

equal to 4.0 than patients who did not progress (84% sustained,

versus 44% unsustained)

-- Almost t
'/>"/>

SOURCE AVONEX
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Panel suggests selling allergy drugs OTC
2. Study suggests symptom driven therapy for adults with asthma
3. Study Suggests Filtering Out Useless Information To Enhance Memory
4. Women Portray Stronger Immune Response As Compared to Men, Study Suggests
5. Meira Kumar Suggests Monitoring Systems To Check Drug Abuse
6. Genetic Mutation in Mice Suggests Extinct Mammoth Had Light and Dark Fur
7. Study Suggests Links Between Diabetes And Multiple Sclerosis
8. New Research Suggests That Obesity Strikes Faster Growing Kids
9. Valve Disease Study Suggests New Public Health Concern
10. Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress
11. Insight Into Tanning Process Suggests Novel Way to Prevent Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its ... signage media player promotion for Dec. 2014. , The ... wave in April, and this promotion will help to expand ... desired models on our website, she/he can contact us with ... new models come in the latest designs, and they actually ...
(Date:11/27/2014)... The American Society for Clinical Pathology (ASCP) announced ... honor of World AIDS Day 2014. On Nov. 25, ASCP ... icon and infographic designed to generate public awareness about World ... , ASCP has asked members to replace their Facebook, Twitter, ... Tested. Find a cure.” icon and share the accompanying infographic ...
(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number 10 ... the 50 fastest-growing technology companies in the UK. Rankings ... years. Cambrionix Ltd grew 2989 percent during this period. ... of Cambridgeshire and East and first in the sector of ... recognition of the hard work put in by our team ...
(Date:11/27/2014)... York (PRWEB) November 27, 2014 ... have been filed in a consolidated litigation now ... reports. , Documents recently updated in the ... included in the state proceeding, all of which ... disorder and other psychiatric conditions. Many of the ...
(Date:11/27/2014)... PA (PRWEB) November 27, 2014 In order ... inventor from Sharpes, Fla., designed an easy way to avoid ... it/them. , He then created a prototype of the patent-pending ... or lower a toilet seat and/or lid in a more ... prevents the spread of germs. Overall, it promotes good hygiene ...
Breaking Medicine News(10 mins):Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4
... all think we know a lot about vitamins, minerals ... studies have created confusion regarding their importance; a simple ... is that “Vitamins and other nutrients, including calcium and ... ,Stressing the point is Dr. Joseph C. Maroon, ...
... forefront of the mission to translate discoveries in basic sciences ... schools to have been chosen to receive a collective grant ... ,"The gap between basic biology and medical practice is ... education at the School of Medicine and principal investigator of ...
... in Russia has been witness to the death of more ... has hit the south of Russia.// ,According to ... Jan 25 and Feb 1, almost 350,000 birds have died ... 76,000 at the Makhachkalinskaya farm between Feb. 6 and Feb. ...
... response of MPs in favor of the proposed smoking ban in ... would be imposed by the summer of next year in the ... 184 has been achieved when the issue of smoking ban extension ... Following implementation of the law, both the public and club/pub workers ...
... mammalian protein called Rad9 could hold the key to killing ... at Washington University School of Medicine in St. Louis. Rad9 ... DNA, but it is now fund to be a "repairman" ... ,That is why reserachers are now ...
... the world's most common liver infection. It spreads easily and ... ,It causes liver cirrhosis, // liver failure and liver ... of the world's population, has been infected with the hepatitis ... are chronic carriers of the virus. Normally in case of ...
Cached Medicine News:Health News:Never undermine the importance of calcium and Vitamin D 2Health News:Getting Basic Science to Work For Medicine 2Health News:Switching Off Protein Could Play Key Role In Success Of Radiation Therapy For Cancer 2
(Date:11/26/2014)... Nov. 26, 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced ... to raise approximately $3.3 million at a price of ... one institutional healthcare focused investor. Each unit consists of one ... share purchase warrant. Each whole warrant entitles the holder ... $0.30 for a period of five years from closing.  ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon ... announced the completion of previously announced concurrent financing ... After fees and estimated offering expenses, Lexicon anticipates ... transactions.  The transactions consisted of: , ... stock, pursuant to a registration statement that has ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: ... (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... and Theravance Inc. (NASDAQ: THRX ). Free research ... . On Tuesday, November 25, 2014, the NASDAQ ... Average edged 0.02% lower, to finish the day at 17,814.94, ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
Classic black cast boot with unisex styling...
... cast boot specially lasted for fiberglass ... rocker sole for easy ambulation! ,The ... narrow last so it fits better ... and with our stretchable upper, a ...
The Multi-Purpose Medical-Surgical Shoe...
The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
Medicine Products: